


NE ZAMAN TEDAVİ VERİLMEZ

Dr. Cemal Bulut


Ankara Eğitim ve Araştırma
Hastanesi

7 Eylül 2013, Sapanca




- Kimler tedavi edilmeli?







- Hepatit B enfeksiyonu dinamik bir süreçtir



- Yeni laboratuvar yöntemleri
 - Daha duyarlı
- Yeni tedavi seçenekleri



*Risk is relative to <10⁴ copies/mL at entry/not tested at follow-up.
Data adjusted for gender, age, cigarette smoking and alcohol consumption using the Cox proportional hazards model.









Causes of death in patients with hepatitis B: a natural history cohort study in the United States.


[Szpakowski JL](#), [Tucker LY](#).


Gastroenterology Department, Kaiser Permanente, Fremont, CA 94538, USA. Jean-Luc.Szpakowski@kp.org

- 1996-2005 yılları arasında
- 3244 kadın ve 3445 erkek
- Sonuç: çalışma döneminde ölen hastaların %40'ında ölüm sebebi HBV ile ilgili
- Erkeklerde bu oran 4 kat fazla









Faz	HBeAg	HBV-DNA	ALT	Histoloji	Tedavi
İmmün toleran	(+)	Çok yüksek >200000IU/ml	Normal	Normal veya hafif inflamasyon	Tdv verimez
İmmün aktif	(+)/(-)	>2000IU/ml >20000IU/ml	Yüksek	İnflamasyon ve fibrosis	Tedavi adayı
İnaktif	(-)	<2000 IU/ml	Normal	Normal veya hafif inflamasyon	Tdv verilmez

- Tedavi kararında önemli olan hastanın karaciğerindeki nekroinflamasyon ve bu durumun ileride siroz yada HCC ile sonuçlanma olasılığı

Occurrence of hepatitis B virus reactivation in inactive HBsAg carriers according to diagnostic pattern and geographic area^a

Author (Reference)	Geographic area	No. of patients	Mean age at entry (yr)	% Males	Mean follow-up (y)	Reactivation	
						No. (%) of patients	Incidence (per 100 person-years)
At presentation^b							
Villeneuve et al. 1994 [4]	Canada	200	29	81	16	1 (0.5) ^c	0.03
Manno et al. 2004 [5]	Italy	124	36	78	30	4 (3) ^d	0.1
Martinot-Peignoux et al. 2002 [23]	France	38	34	54	3.2	1 (2) ^d	0.8
Chu and Liaw 2007 [24]	Taiwan	1241	35	53	12	211 (17) ^d	1.4
During follow-up^e							
Fattovich et al. 2008 [12]	Italy	61	30	67	18	9 (14) ^d	0.8
McMahon et al. 2001 [25]	Alaska	541	20	59	12.6	109 (20) ^c	1.6
Hsu et al. 2002 [26]	Taiwan	283	32	81	8.6	68 (24) ^d	2.8
Chu et al. 2004 [8]	Taiwan	204	31	na	6.8	36 (17) ^d	2.6

Karaciğer histolojisi:

- Genellikle normal
- %1-13 hafif orta derece fibrosis olabilir
- Uzun süreli takipte ciddi değişiklik yok

Hepatoselüler karsinoma

Overall hepatocellular carcinoma incidence and liver-related death rates in longitudinal studies of patients with chronic hepatitis B virus infection according to clinical status and geographic area^a

Clinical status	Geographic area	HCC			Liver-related death		
		Incidence ^b	95% CI	Mean follow-up (y)	Rate ^b	95% CI	Mean follow-up (y)
Inactive carrier ^c	Europe	0.02	0–0.05	19.6	0.03	0–0.07	19.9
	Taiwan	0.2	0–0.42	8	–	–	–
Asymptomatic carrier	Europe, North America	0.04	0.03–0.5	19	0.09	0.08–0.11	19.7
	Taiwan, China, Korea, Japan	0.5	0.49–0.55	9	0.8	0.72–0.85	8.7
Chronic hepatitis ^d	Europe, USA	0.3	0.12–0.41	6	0	0	5.5
	Taiwan, China, Korea, Japan	0.6	0.53–0.72	6.6	0.6	0.31–0.83	13.5
Compensated cirrhosis ^e	Europe, USA	2.2	1.71–2.71	6	3.3	2.28–4.4	6.2
	Taiwan, China, Singapore, Japan	3.7	4.14–16.76	6	2.9	2.34–3.52	8

EASL kılavuzuna göre tedavi indikasyonları


	Hepatit		Siroz	
	HbeAg(+)	HbeAg (-)	Kompanze	Dekompanze
ALT	>ULN	>ULN	Her değer	Her değer
VİRAL YÜK	>2.000 IU/ml	>2.000 IU/ml	POZİTİF	POZİTİF
KC Biyopsi	Orta/ileri inflamasyon veya fibrozis			

Kılavuzlara göre tedavi indikasyonları

- Akut karaciğer yetmezliği,
- Siroz ve koplikasyonlarının varlığı,
- Yüksek HBV-DNA' sı alan hastalarda siroz veya ileri derece fibrozis varlığı,
- Kemoterapi veya immünsüpresyon nedeniyle HBV reaktivasyonunun önlenmesi

Tedavi önerilmeyen hastalar

- İmmüntoleran fazda olan hastalar (yüksek serum HBV DNA seviyesi ve normal serum ALT seviyesi veya KC biyopsisinde düşük aktivasyon bulguları olan hastalar)
- İnaktif taşıyıcılık fazında olan hastalar (HBV-DNA'sı düşük veya tespit edilemeyen ve normal ALT seviyesinde olan hastalar)
- Latent HBV enfeksiyonu olan hastalar (HBsAg olmaksızın HBV-DNA pozitifliği)




Ancak...

- Gerçek HbsAg taşıyıcılarını kronik hepatit B'den ayırmak çok güç olabilir.
- Böyle hastalar yeterli süre uygun aralıklarla düzenli olarak takip edilmelidir
- HBV-DNA < 2000 IU/ml ise altı aylık takip
- HBV-DNA 2000-20000 ise 3 aylık aralıklarla uzun süreli takip (en az 3 yıl)


- Örnekler

ME, 41y, K, HBeAg (-)



HBV-DNA (Kan) Sonuç Grafiği




ALT (Kan) Sonuç Grafiği



EE, 21y, K, HBeAg (-)



BE, 17y K, HBeAg (+) HBV-DNA:>10⁹



Makroskopi :

Büyüğü 2,3 cm, küçüğü 0,2 cm boyutlarında karaciğer iğne biyopsi materyali. T3P2K (TA) (SH) (MG)

Mikroskopi :

Tanı :

-MİNİMAL KRONİK HEPATİT;

-MODİFİYE HAI: 3/18

-Portal inflamasyon: 1

-Bütün portal bölgeler çevresinde fokal lezyon (Güve yeniği nekrozu): 0

-Her lobülde birden fazla nekroinflamatuvar odak (Fokal "Spotty" lobüler nekroz): 2

-Köprüleşme nekrozu: Yok (0/6)

-FİBROBLASTİK EVRE: 0/6

Karaciğer, İğne biyopsisi

AT, 36, K,

- ALT:41,
- AST:41
- HBV-DNA:18 864 640
- HBsAg (+), HBeAg (-)
- Modifiye HAI:8
- EVRE:2

- MD, 45Y, E,
- HBe Ag negatif

	TEMMUZ 2012	TEMMUZ 2013
ALT	17	16
AST	21	21
HBV-DNA	3994	2400

KC Biyopsisi: Modifiye Hai: 5
Evre:2

- NP, 51Y, E,
- 2003 yılında HBsAg pozitif saptanmış.

	KASIM 2008	HAZİRAN 2009	MART 2010	MART 2011	MART 2012	ARALIK 2012	TEMMUZ 2013
ALT	27	26	60	43	52	55	49
AST	28	82	40	27	36	44	33
HBV-DNA	1308	1343	1043	3529	3068	1318	4641



KC Biyopsi:

Knodell :4

Evre :2

- CA, 25, E
- 2008de askerde saptamış
- Hbeag negatif

KC Biyopsi
Knodel: 5
Evre :2



- KK,35Y, E,
- 2000 yılında askerde HBsAg (+)

	ARALIK 2009	MART 2010	ARALIK 2011	HAZİRAN 2012	ARALIK 2012	TEMMUZ 2013
ALT	23	36	30	31	30	28
AST	24	28	28	32	28	28
HBV- DNA	2486	3796	1514	1153	1011	3624

KC biyopsisi

Knodell skoru :5

Evre :2

devam edecek.....